Stifel Nicolaus analyst Thomas Stephan upgraded Sight Sciences (SGHT – Research Report) to a Buy on January 27 and set a price target of $15.00. The company’s shares closed last Friday at $12.84.
According to TipRanks, Stephan is ranked #6530 out of 8269 analysts.
Sight Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $14.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $18.25 and a one-year low of $5.35. Currently, Sight Sciences has an average volume of 145.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company’s product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company’s non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.
Read More on SGHT:
- Sight Sciences announces 1,000th TearCare customer installation
- Sight Sciences Announces 1,000th TearCare® Customer Installation
- Sight Sciences sees FY22 revenue $71.2M-$71.4M, consensus $70.93M
- Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
- Stifel upgrades Sight Sciences to Buy on potential 2023 upside
